Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Open Label, Multiple-Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of BMS-824393 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1

The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.

Inclusion Criteria:

• Treatment naive chronically infected subjects with Hepatitis C Virus genotype 1
• HCV RNA viral load of ≤10*5* IU/mL (100,000 IU/mL)
• Body Mass Index (BMI) of 18 to 35 kg/m², inclusive

Exclusion Criteria:

• Women who are pregnant or breast feeding
• Any significant acute or chronic medical illness which is not stable or is not controlled with medication or is not consistent with Hepatitis C infection
• Any other medical, psychiatric and/or social reason which, in the opinion of the Investigator, would make the candidate inappropriate for participation in this study